H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of ...

H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...

Vaccine maker shares closed lower Thursday amid reports that Donald Trump was set to nominate vaccine critic Robert F.

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

This class of drug has been attracting increased interest for deals. On Wednesday, German drugmaker BioNTech said it would ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...

(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...